For most of the past two years, oral incretins meant one thing: semaglutide tablets taken on an empty stomach with precise water restrictions. That is about to stop being the whole story. In the past fortnight, the non-peptide oral GLP-1 candidates have published the phase 3 data that turns them from pipeline slides into a real class - and the head-to-head result against oral semaglutide did not go the way many expected.
What the Research Says
Three publications anchor the wave:
Orforglipron versus oral semaglutide, head-to-head. The ACHIEVE-3 trial, published in The Lancet (DOI: 10.1016/S0140-6736(26)00202-3), randomised 1,698 adults with type 2 diabetes across five countries to orforglipron 12 mg or 36 mg, or oral semaglutide 7 mg or 14 mg, for 52 weeks. Both orforglipron doses were non-inferior and superior to both semaglutide doses on HbA1c reduction: -1.91% at 36 mg versus -1.47% on semaglutide 14 mg, from a baseline of 8.3%. On weight, the pattern held. The costs were honest too: more GI events (58-59% versus 37-45%), more discontinuations (9-10% versus 4-5%), and a larger pulse bump (+4.7 bpm at 36 mg).
Cardiovascular safety confirmed. A separate event-driven phase 3 trial published in The Lancet on September 30 (PIIS0140-6736(26)01865-9) tested whether a non-peptide GLP-1 is safe in the heart, the question class skeptics kept asking. In 2,749 adults with type 2 diabetes and elevated cardiovascular risk, orforglipron was non-inferior to insulin glargine for major adverse cardiovascular events over a median of two years (HR 0.84, 95% CI 0.59-1.20). It also came with 19.2% versus 6.8% hypoglycaemia favouring the pill against insulin - a needle-mover for the GLP-1-versus-insulin conversation.
Safiglipron in a different class fight. Nature Medicine published OUTSTAND-2 (s41591-026-04713-y), where oral small-molecule safiglipron at 30, 60 and 90 mg was non-inferior to dapagliflozin - an SGLT2 inhibitor, not another GLP-1 - across 810 participants, with the 90 mg dose winning on the stricter superiority test. Body weight fell up to 4.17% on safiglipron versus 3.60% on dapagliflozin.
Why the Mechanism Label Matters
“Orforglipron” and “safiglipron” are not peptides. They are small molecules that activate the GLP-1 receptor - which is the whole commercial point. Peptides need cold-chain logistics, injection or specialised oral absorption, and fermentation-scale manufacturing. Small molecules are shelf-stable pills that a contract factory can make by the tonne.
That matters in Australia more than most places. Cold-chain peptide distribution to regional and remote areas is genuinely hard, and manufacturing scale is what turns a scarce, expensive drug into a common one. We covered the access dynamics in our telehealth gatekeeping piece. The small-molecule class is the first credible path to GLP-1 effect without cold chain or injectables.
The trade-offs are visible in the data already: the oral small molecules carry more GI burden and slightly larger heart-rate increases than their peptide cousins, and aleniglipron’s phase 2b in obesity (Nature Medicine, s41591-026-04476-6) showed up to 11.3% placebo-adjusted weight loss at 36 weeks with GI discontinuations around 10%. Nothing disqualifying, but nothing free.
The Australian Angle
None of these compounds is approved by the TGA yet. Orforglipron has cardiovascular safety data in print and pending regulatory filings; safiglipron and aleniglipron are earlier. When filings land, expect the same access debates we saw with semaglutide and tirzepatide, with one new twist: if supply is no longer the constraint, the argument shifts entirely to cost and eligibility.
Until approval, any “oral GLP-1” sold outside the prescription system in Australia is unapproved product, and the TGA’s compliance priorities for 2026-27 explicitly target unapproved peptides and weight-loss medicines - see our TGA compounding pharmacy update for the enforcement landscape.
For how the approved incretins compare, our semaglutide and tirzepatide pages cover the landscape. Deep dives welcome in the Telegram community.
Sources
- The Lancet, published 2026: ACHIEVE-3, orforglipron versus oral semaglutide, DOI: 10.1016/S0140-6736(26)00202-3, NCT06045221
- The Lancet, published September 30, 2026: Orforglipron cardiovascular outcomes versus insulin glargine, NCT05803421
- Nature Medicine, 2026: Safiglipron versus dapagliflozin (OUTSTAND-2), NCT06589765
- Nature Medicine, 2026: Aleniglipron phase 2b in obesity (ACCESS), NCT06693843
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.